Navigation Links
Intro of Pneumococcal Vaccines: Experts Urge Commitment From Industry

In today's online edition of The Lancet, a group of leading global health experts have come together to call for vaccine manufacturers and international donors// to negotiate affordable pricing of pneumococcal conjugate vaccines and for governments of developing world countries and their partners to establish disease surveillance networks and begin preparations for pneumococcal vaccine introduction.

The experts believe that urgent action to introduce routine childhood pneumococcal vaccination is needed because of the enormous burden of the disease - the World Health Organisation (WHO) estimates that about 1.6 million people including up to one million children under five years old, die every year of pneumococcal pneumonia, meningitis, and sepsis.(1) In populations with high child mortality rates, pneumonia is the leading infectious cause of mortality and accounts for about 20-25% of all child deaths.(2) This call to action comes on the eve of a meeting of G8 ministers to discuss funding vaccines.

This seems to be the latest step in major changes over the last five years in financing of immunisation, including the creation of the GAVI Alliance (Global Alliance for Vaccines and Immunization) Fund. Dr Orin Levine, the lead author of the article and Executive Director of PneumoADIP - a non-governmental organisation that aims to shorten the time between use of a vaccine in industrialised nations and their introduction in the developing world - commented: ‘We hope that with such mechanisms in place, all developing countries will begin to consider that millions of children can now be saved by the simple addition of this vaccine to existing immunisation programmes.’

Dr Thomas Cherian, Co-ordinator, Ad Interim, EPI, WHO, and co-author of the article added: ‘Pneumococcal disease is a major global health issue; what is promising is that a seven-valent vaccine that is effective against seven c ommon strains of the disease is already licensed and in use in over 60 countries and that formulations containing additional serotypes of the organism that are also relevant for developing countries are under development. The WHO considers pneumococcal vaccines to be a priority and recognises the urgency to make these vaccines available for children in developing countries.’

There are other pneumococcal vaccines in development, which contain additional serotypes targeting strains of the disease that commonly cause death and disability in the developing world; however, these will not be available for several years. Introducing the seven-valent vaccine now means that lives can start to be saved straight away. This vaccine, manufactured by Wyeth, is effective, well-tolerated and can be delivered through existing immunisation systems. Surveillance data from the USA indicate that the herd immunity(i) effect from routine childhood pneumococcal vaccination prevents twice as many cases as the direct effects of vaccination alone - protecting vulnerable adults as well as children.

Responding to The Lancet paper, Julian Lob-Levyt, Executive Secretary, GAVI Alliance, said, ‘There is convincing evidence of the benefits of vaccines for major child killers especially when such a simple health intervention could help in meeting UN Millennium Development Goal no. 4: to reduce child mortality by two thirds by 2015. GAVI will be looking closely at how best to assist countries where pneumococcal disease represents a significant burden on public health.’

Jean Stephenne, President of GlaxoSmithKline Biologicals, the vaccines division of GlaxoSmithKline PLC, also welcomed the call to action in The Lancet and said, ‘GSK Bio has invested many years in the development of a vaccine that protects against the 10 most important strains of pneumococcus serotypes worldwide, and our candidate is now being stud ied in a global clinical program. We have a long history of supplying vaccines in developing countries and are committed to working to make our pneumococcal vaccine available worldwide at sustainable prices. We hope that our partners in governments, donor agencies, charities, and international organisations will step up with a firm purchase commitment that will allow us to save as many lives as possible.’

James Connolly, Executive Vice President and General Manager of Wyeth Pharmaceuticals vaccine's business unit, concurred with the call to action and stated, ‘Prevnar has been launched in 60 countries, and has had a significant impact on the health of children where it is in use. In the US, three years after the routine use of Prevnar, there has been a 94 per cent reduction in invasive pneumococcal disease caused by the disease serotypes included in the vaccine. We are actively working with international agencies to help provide access to Prevnar for children in the developing world.

Meanwhile, Wyeth researchers are continuing to work on new versions of Prevnar, including a version that will address 13 of the most prevalent serotypes of invasive pneumococcal disease, which will expand its usefulness globally for both children and adults.’

Source: TI news
'"/>




Related medicine news :

1. TI Cycles Introduces Foldman
2. Canada Introduces Mandatory Nutrition Labeling
3. Bill to Ban Abortion In Indiana Introduced
4. Ramdoss Announces Introduction of RCH-II
5. Haryana To Introduce Ramdevs Yoga For School Students
6. NACO to Introduce 400 Additional AIDS/HIV Screening Centers
7. International Rating System To Be Introduced For Hospitals In India
8. Introduction of Microbial Organisms: A Possible Treatment for Asthma
9. Earlier Introduction of Solid Foods in Infants Could Prevent Wheat Allergy
10. Goa To Introduce Bond For Medicos
11. Three New Contraceptives Introduced by HLL
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group ... Tournament held on June 20th at the Woodmont Country Club at 1201 Rockville ... an organization dedicated to helping service members that have been wounded in battle and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology: